CompletedEUCTR 2004-000707-18

A 40-week open, flexible dose, extension study of bifeprunox in patients with schizophrenia.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

SchizophreniaDrug

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Need help deciding?

Ask HopeStage to review this study with me

Study ID: EUCTR 2004-000707-18. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Historical registry record checked by HopeStage on 15 September 2026. Registry information can change. Always confirm availability with the research team.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

View the historical EU CTR record

Historical EU CTR country statuses

Italy : Completed

No specific site is confirmed in the available information. Check the official source for locations and remote participation.

In plain English

Key information made simple

What the source confirms

What should you check before joining?

Check the official protocol for eligibility, treatment, visits and assessments. If recruitment is listed, confirm with the team that a specific centre is still accepting participants before taking any next step.

What to expect

Your next step

Participation locations and format are not confirmed in the available information. Ask the research team to confirm the location, any in-person visits, time commitment, costs or compensation, and participation criteria.

Before joining

Questions to ask before joining

What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?

Study clarity

Things to check before joining

Study start dateNot clearly listed

Recruitment status: Completed
Enrollment listed in the registry: 480
Sponsor: LUNDBECK ITALIA
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Italy
Age range: Not clearly listed
Official registry ID: EUCTR 2004-000707-18
Official title: A 40-week open, flexible dose, extension study of bifeprunox in patients with schizophrenia.
Official source: Official registry link

Want help reviewing this study?

Study ID: EUCTR 2004-000707-18. We help you review the study, but cannot decide medical eligibility.

In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Confirm the location and whether remote participation is possible with the research team.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What does the official source confirm?

Is this study recruiting?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

How can I check the participation requirements?

Check the official protocol for the criteria, treatment and planned assessments. The research team must confirm visits, risks, open centres and your eligibility.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me